Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
ARLINGTON, Va., April 12, 2016 -- FBR & Co. (Nasdaq:FBRC) (FBR), a leading investment bank serving the middle market, announced that Chris Meekins recently joined its equity research group and has initiated coverage on healthcare policy. Mr. Meekins is based in the Company’s Arlington, VA headquarters.
“Chris’s addition to our team brings a meaningful and unique policy perspective to our healthcare research that our clients want,” said FBR’s Director of Research and Senior Managing Director, David Hilal. “We have a great tradition of weaving together actionable investment ideas that are at the intersection of government policy and fundamental analysis. For the healthcare industry in particular, this differentiated approach provides our clients with tremendous value.”
Mr. Meekins came to FBR having spent four years as a senior health policy advisor and Chief of Staff for Congressman Andy Harris, M.D. During his tenure there, he helped pass reforms to the National Institutes of Health, increase funding for bio-defense, expand access to organs for transplantation, improve Medicare payments for physicians and increase transparency at the Food and Drug Administration. Before serving on the Hill, he worked in government affairs for the American Society of Anesthesiologists. Mr. Meekins holds a Bachelors of Arts from Gardner-Webb University.
FBR & Co. (Nasdaq:FBRC) provides investment banking, merger and acquisition advisory, institutional brokerage, and research services through its subsidiaries FBR Capital Markets & Co. and MLV & Co. FBR focuses capital and financial expertise on the following industry sectors: consumer; energy & natural resources; financial institutions; healthcare; industrials; insurance; real estate; and technology, media & telecom. FBR is headquartered in the Washington, D.C. metropolitan area with offices throughout the United States. For more information, please visit www.fbr.com.
Contacts Media: Shannon Hawkins at 703.469.1190 or [email protected] Investors: Linda E. Eddy at 703.312.9715 or [email protected]
